Bank of Nova Scotia FWP Offers High-Leverage Notes Tied to DELL, INTC, LLY
Rhea-AI Filing Summary
Bank of Nova Scotia (BNS) has filed a Free Writing Prospectus for Series A senior market-linked securities that are auto-callable, principal-at-risk notes linked to the worst performer among Dell Technologies (DELL), Intel (INTC) and Eli Lilly (LLY). Each note is issued in $1,000 denominations, is expected to price on June 26 2025 and settle on July 1 2025, with a stated maturity of June 29 2028, unless automatically called earlier.
Automatic call feature: if on the one-year call date (July 1 2026) the lowest-performing stock closes at or above its starting price, investors receive face value plus a ≥ 50 % call premium (≥ $500), forfeiting any further upside.
Maturity payoff (if not called):
- Bullish scenario: worst-performer ends above its start; payment equals $1,000 plus 350 % of that stock’s price return.
- Sideways scenario: worst-performer ends between 50 % and 100 % of start; principal is returned.
- Bearish scenario: worst-performer ends below 50 % of start; investor loses 1-for-1 with the stock, exposing more than 50 %—up to full—principal loss.
The preliminary internal value is $900-$931.30 (90-93.13 % of face), reflecting dealer spreads and hedging costs. Notes pay no periodic interest, are unsecured obligations of BNS, and lack FDIC insurance or active secondary liquidity. Scotia Capital Inc. acts as calculation agent; Scotia Capital (USA) and Wells Fargo Securities distribute the product, receiving up to 2.575 % in selling concessions.
Key risks highlighted include full downside below the 50 % threshold, dependence on the single worst-performing stock, BNS credit risk, liquidity constraints, potential conflicts of interest, and uncertain tax treatment.
Positive
- None.
Negative
- None.
Insights
TL;DR: High upside (350 %) and 50 % buffer, but full downside risk, no coupons, and estimated value only 90-93 % of par.
The term sheet offers investors leveraged equity exposure with a short one-year auto-call and an attractive ≥ 50 % call premium. The 350 % participation above par after three years is competitive versus peers. However, the structure concentrates risk in the single worst performer of three volatile equities. Once prices breach the 50 % threshold, losses are linear, exposing investors to > 50 % capital loss. The initial estimated value—up to 10 % below face—illustrates high embedded costs. No periodic coupons translate into negative carry, while illiquid secondary markets make exit costly. Credit exposure to BNS, though investment-grade, remains another layer of risk. Overall, risk/return is balanced; material impact to BNS’s financials is immaterial.
TL;DR: Product is niche and neutral for BNS; investors face concentrated downside, limited liquidity, and reinvestment risk.
From a risk-management lens, the note’s appeal rests on the 50 % downside buffer and the possibility of a quick auto-call. Yet buffer effectiveness relies on three highly correlated tech-healthcare names; historical shocks show simultaneous drawdowns are plausible. Absence of periodic coupons removes income diversification, while early call forces reinvestment at uncertain rates. The worst-of design creates path-dependency, and the calculation agent is an affiliate, raising conflict considerations. Given BNS’s large balance sheet, issuance size is unlikely to shift credit metrics; thus capital-markets impact is negligible. I view the disclosure as routine, with no directional signal on BNS shares.